Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Atezolizumab + Bevacizumab |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Atezolizumab | Tecentriq | RG7446|MPDL3280A | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive (IC >/= 5%) advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>/=50% or IC>/=10%) and without EGFR or ALK alterations, for adjuvant treatment in patients with PD-L1-positive (>=1% tumor cell expression) NSCLC, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib) in unresectable or metastatic BRAF V600-mutated melanoma, and in pediatric and adult patients with unresectable or metastatic alveolar soft part sarcoma (FDA.gov). |
| Bevacizumab | Avastin | VEGF Antibody 12 VEGFR Inhibitor (Pan) 36 | Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04510584 | Phase II | Atezolizumab + Bevacizumab | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer | Withdrawn | CAN | 0 |
| NCT04829383 | Phase II | Atezolizumab + Bevacizumab | A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma (AB7) | Active, not recruiting | USA | 0 |
| NCT04732286 | Phase III | Atezolizumab + Bevacizumab | A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy | Completed | ESP | 0 |
| NCT05776875 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | Recruiting | USA | 0 |
| NCT04857684 | Phase I | Atezolizumab + Bevacizumab | SBRT + Atezolizumab + Bevacizumab in Resectable HCC | Recruiting | USA | 0 |
| NCT05448677 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + GNS561 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma (ABE-LIVER) | Terminated | FRA | 0 |
| NCT05665348 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + Ipilimumab | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET) | Recruiting | FRA | 0 |
| NCT05180006 | Phase II | Atezolizumab Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab | Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program) | Recruiting | FRA | 0 |
| NCT05904886 | Phase III | Atezolizumab + Bevacizumab + Tiragolumab Atezolizumab + Bevacizumab | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14) | Recruiting | USA | TUR | POL | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BEL | 14 |
| NCT04487067 | Phase III | Atezolizumab + Bevacizumab | A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista (AMETHISTA) | Completed | ITA | 0 |
| NCT04727307 | Phase II | Atezolizumab + Bevacizumab | Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial (AB-LATE02) | Recruiting | FRA | 0 |
| NCT05488522 | Phase I | Atezolizumab + Bevacizumab | SBRT With Atezo/Bev for HCC | Recruiting | USA | 0 |
| NCT05690048 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + Fecal microbiota + Vancomycin | Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) (FLORA) | Not yet recruiting | DEU | 0 |
| NCT03654833 | Phase II | Bemcentinib + Pembrolizumab Rucaparib Abemaciclib Atezolizumab + Bevacizumab Dostarlimab-gxly + Niraparib | Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (MiST) | Active, not recruiting | GBR | 0 |
| NCT04486352 | Phase Ib/II | Atezolizumab + Talazoparib Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab | A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer (EndoMAP) | Recruiting | USA | 0 |
| NCT03181100 | Phase II | Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | Active, not recruiting | USA | 0 |
| NCT04931342 | Phase II | Cobimetinib Ado-trastuzumab emtansine Ipatasertib + Paclitaxel Atezolizumab + Bevacizumab | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | Active, not recruiting | USA | TUR | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUS | 2 |
| NCT05359861 | Phase II | Atezolizumab + Bevacizumab + SRF388 Atezolizumab + Bevacizumab | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | Active, not recruiting | USA | AUS | 2 |
| NCT04224636 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab (DEMAND) | Recruiting | DEU | 0 |
| NCT05620771 | Phase II | Yttrium-90 microsphere therapy Atezolizumab + Bevacizumab | Therasphere and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk | Recruiting | USA | 0 |
| NCT04721132 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | Active, not recruiting | USA | 0 |
| NCT03818061 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (ATHENA) | Active, not recruiting | FRA | 0 |
| NCT06096779 | Phase II | Atezolizumab + Bevacizumab Atezolizumab | A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis (Kirros) | Recruiting | USA | 1 |
| NCT03526432 | Phase II | Atezolizumab + Bevacizumab | Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT04563338 | Phase II | Atezolizumab Atezolizumab + Bevacizumab | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | Recruiting | CAN | 0 |
| NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
| NCT03272217 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | Terminated | USA | 0 |
| NCT04803994 | Phase III | Atezolizumab + Bevacizumab | The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | Recruiting | ITA | FRA | ESP | DEU | AUT | 1 |
| NCT04817956 | Phase II | Ceritinib Melphalan Cobimetinib + Vemurafenib Alectinib Pemigatinib Entrectinib Bortezomib Dostarlimab-gxly Atezolizumab Alpelisib Atezolizumab + Bevacizumab Olaparib Selpercatinib Capmatinib Dactinomycin Dabrafenib + Trametinib Vismodegib Niraparib Imatinib Pertuzumab/trastuzumab/hyaluronidase-zzxf | Improving Public Cancer Care by Implementing Precision Medicine in Norway (IMPRESS-N) | Recruiting | NOR | 0 |
| NCT05482516 | Phase III | Atezolizumab + Bevacizumab | Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI) | Recruiting | USA | 0 |
| NCT04102098 | Phase III | Atezolizumab + Bevacizumab | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050) | Active, not recruiting | USA | TUR | POL | NZL | NLD | ITA | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 11 |
| NCT03434379 | Phase III | Atezolizumab + Bevacizumab Sorafenib | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] | Completed | USA | POL | ITA | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 7 |
| NCT03896074 | Phase II | Atezolizumab + Bevacizumab Atezolizumab | Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT) | Unknown status | ITA | 0 |
| NCT04739202 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Ipatasertib | Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (IMMUNOGAST) | Unknown status | FRA | 0 |
| NCT05185505 | FDA approved | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | Recruiting | USA | 0 |
| NCT04541173 | Phase II | Atezolizumab + Bevacizumab | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) | Terminated | USA | 0 |
| NCT05063552 | Phase II | Bevacizumab + Cisplatin + Docetaxel Carboplatin + Cetuximab + Docetaxel Bevacizumab + Carboplatin + Docetaxel Cetuximab + Cisplatin + Docetaxel Atezolizumab + Bevacizumab | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | Recruiting | USA | 0 |
| NCT05908786 | Phase Ib/II | Bevacizumab + RO7247669 Atezolizumab + Bevacizumab + Tiragolumab Atezolizumab + Bevacizumab | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | Recruiting | USA | NZL | GBR | FRA | ESP | DEU | AUT | 2 |
| NCT02921269 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer | Completed | USA | 0 |
| NCT03175432 | Phase II | Atezolizumab + Bevacizumab | Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases (BEAT-MBM) | Active, not recruiting | USA | 0 |
| NCT05096715 | Phase I | Atezolizumab + Bevacizumab | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | Recruiting | USA | 0 |
| NCT04524871 | Phase Ib/II | Atezolizumab + Bevacizumab + Tocilizumab Atezolizumab + Bevacizumab + Tiragolumab Atezolizumab + Bevacizumab | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | Recruiting | USA | NZL | ISR | FRA | 3 |
| NCT02982694 | Phase II | Atezolizumab + Bevacizumab | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer | Terminated | NLD | ITA | ESP | BEL | 0 |
| NCT05528952 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + UCPVax | Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma (TERTIO) | Recruiting | FRA | 0 |
| NCT04017455 | Phase II | Bevacizumab Atezolizumab Atezolizumab + Bevacizumab | Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN) (TARZAN) | Unknown status | NLD | 0 |
| NCT04099836 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib | Terminated | USA | 0 |
| NCT05537402 | Phase II | Atezolizumab + Bevacizumab | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST- B) Trial (LOST-B) | Recruiting | USA | 0 |
| NCT06109272 | Phase II | ABBV-151 + Budigalimab Atezolizumab + Bevacizumab Durvalumab + Tremelimumab | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | Recruiting | USA | ITA | FRA | ESP | 2 |
| NCT04356729 | Phase II | Atezolizumab + Bevacizumab | A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma | Recruiting | USA | 0 |
| NCT05717400 | FDA approved | Atezolizumab + Bevacizumab | Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy | Terminated | USA | 0 |
| NCT02715531 | Phase I | Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | Completed | USA | NZL | AUS | 4 |
| NCT03424005 | Phase Ib/II | Atezolizumab + Bevacizumab + Selicrelumab Atezolizumab + RO6874281 Atezolizumab + Bevacizumab Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Eribulin Capecitabine Atezolizumab Atezolizumab + Bevacizumab + Cobimetinib Atezolizumab + Capecitabine Atezolizumab + Ipatasertib Atezolizumab + Ladiratuzumab vedotin | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | AUS | 1 |
CKB BOOST